Sport Integrity Australia acknowledges that Ice Hockey Australia has imposed an 18-month period of Ineligibility on athlete Austin Albrecht for the Anti-Doping Rule Violations (ADRVs) of Presence of a metabolite of a Prohibited Substance and Use of a Prohibited Substance.
Mr Albrecht returned an Adverse Analytical Finding from an In-Competition doping control test on 24 August 2024. Mr Albrecht’s sample was analysed at the Anti-Doping Laboratory LSI Medience Corporation in Tokyo, Japan, and the presence of Amfetamine (a metabolite of Lisdexamfetamine), was detected.
Lisdexamfetamine is listed under Class S6.A (Non-Specified Stimulants) of the World Anti-Doping Code – International Standard – Prohibited List 2024. Lisdexamfetamine is classed as a Non-Specified Substance and prohibited in competition only.
In accordance with Article 10.2.1 of the Australian National Anti-doping Policy 2021 (ANADP), Mr Albrecht established that the ADRVs were not committed intentionally. Mr Albrecht also received a reduction to his sanction on the basis of No Significant Fault or Negligence under Article 10.6 of the ANADP.
Ice Hockey Australia has imposed an 18-month period of Ineligibility on Mr Albrecht to commence from 24 March 2026. Mr Albrecht did not receive credit for his provisional suspension as he competed in the Federal Prospects Hockey League in the US for the 2025-26 season, which he was prohibited from doing so during his provisional suspension under Article 10.14.1 of the ANADP.
In accordance with Article 10.10 of the ANADP, any medals, points or prizes obtained by Mr Albrecht from 24 August 2024 onwards, shall be forfeited.
Mr Albrecht is ineligible to participate in any sports that have adopted a World Anti-Doping Code compliant anti-doping policy until 11:59pm 9 June 2027. He is also not permitted to compete in a non-signatory professional league, or event organised by a non-signatory International or National level event organisation.
Additional information on the Prohibited Substance
Lisdexamfetamine is a stimulant drug commonly used in the treatment of attention deficit hyperactivity disorder (ADHD).
Stimulant medications, such as Methylphenidate (for example Ritalin, Concerta), Dexamphetamine and Lisdexamphetamine (for example Vyvanse) are prohibited In-Competition and require a Therapeutic Use Exemption (TUE).
Sport Integrity Australia recommends you check all your substances before you take them on the Sport Integrity App.